Genetic Variation in Platelet Aggregation

Completed

Conditions studied: Myocardial Infarction

In brief

The aim of the study is to test whether genetic variation in the alpha 2A adrenergic receptor affects diurnal variation in platelet aggregation.

Key facts

Study ID

NCT01576536

Run by

Vanderbilt University

People needed

117

Starts

2012-07-01

Expected to finish

2016-12-01

Last updated by the study team

2019-06-05

Who can join

Age: 18 and older, up to 45. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Men and women aged 18 - 45 years inclusive.
• Women of the above age will be studied between day 1 and day 14 of a normal menstrual cycle.
• Subjects must be willing to give informed consent for the study and able to adhere to the study diet and study procedures.
• Subjects and immediate extended family up till grandparents will be Caucasians or African Americans only.
• Subjects will be free of any clinically significant disease.
• Clinical laboratory test (CBC, blood chemistry) will be within acceptable limits.

You may not qualify if…

• Subjects who have taken any antiplatelet, anticoagulant or procoagulant medicines within the last three weeks preceding the study.
• Subjects who have taken medications (including over the counter medications) other than oral contraceptives in the past two weeks.
• Subjects who smoke or have smoked in the past 3 months.
• Subjects who are presently or were formerly a narcotic addict or alcoholic.
• Females with a positive pregnancy test.
• Females who are breast feeding.

Where it is running

• the Vanderbilt University General Clinical Research Center — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.